Welcome to our dedicated page for Bicara Therapeutics news (Ticker: BCAX), a resource for investors and traders seeking the latest updates and insights on Bicara Therapeutics stock.
Bicara Therapeutics (BCAX) is a clinical-stage biopharmaceutical company advancing novel bifunctional antibodies designed to treat solid tumors by simultaneously targeting EGFR and TGF-β pathways. This page provides investors and researchers with timely updates on clinical trials, regulatory milestones, and scientific developments.
Access the latest press releases, peer-reviewed data, and strategic partnership announcements in one centralized location. Key updates include progress on lead candidate ficerafusp alfa, trial design insights for head and neck cancers, and analyses of tumor microenvironment modulation strategies.
Content spans clinical trial phases, FDA communications, research collaborations, and financial disclosures. All materials are curated to support informed analysis of Bicara’s therapeutic pipeline and oncology innovation strategy.
Bookmark this page for streamlined access to verified updates on Bicara’s progress in developing precision therapies for underserved cancer indications.
Bicara Therapeutics (Nasdaq: BCAX) announced it will present updated data from its ongoing Phase 1/1b clinical trial of ficerafusp alfa at the 2025 ASCO Annual Meeting. The presentation will focus on the drug's application in first-line recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
Ficerafusp alfa is a first-in-class bifunctional antibody targeting both EGFR and TGF-β, being evaluated across multiple solid tumor types. The data, to be presented on June 1, 2025, will showcase updated survival and durability results specifically for HPV-negative R/M HNSCC patients, who typically face worse prognosis and poorer outcomes compared to HPV-positive cases.
Bicara Therapeutics (NASDAQ: BCAX) has reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical programs. The company commenced dosing in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa for first-line recurrent/metastatic head and neck squamous cell carcinoma.
Financial highlights include a strong cash position of $489.7 million as of December 31, 2024, expected to fund operations into first half of 2029. The company reported Q4 R&D expenses of $19.9 million and G&A expenses of $6.8 million, with a net loss of $21.0 million. Full-year 2024 results showed R&D expenses of $63.6 million, G&A expenses of $18.8 million, and a net loss of $68.0 million.
The company will present updated data from its ongoing Phase 1/1b trial at the 2025 ASCO Annual Meeting and has multiple expansion cohorts planned across various cancer types, including colorectal cancer and HPV-positive patients.
Bicara Therapeutics (Nasdaq: BCAX) has announced three abstract presentations featuring their lead product ficerafusp alfa at the upcoming AACR Annual Meeting 2025 in Chicago (April 25-30, 2025).
The presentations will showcase:
- Dose expansion results of ficerafusp alfa monotherapy in advanced cutaneous squamous cell carcinoma (cSCC) patients
- Data on dual blockade of EGFR and TGF-β with ficerafusp alfa in combination with Pembrolizumab for HNSCC treatment
- Preclinical findings on how ficerafusp alfa reverses resistance to sotorasib in KRAS-G12C-mutated lung tumors
Ficerafusp alfa is a first-in-class bifunctional antibody targeting both EGFR and TGF-β, currently being evaluated across multiple solid tumor types.
Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, has announced its participation in the TD Cowen 45th Annual Health Care Conference. Claire Mazumdar, PhD, MBA, Chief Executive Officer, will deliver a presentation on Monday, March 3, 2025, at 3:10 p.m. ET.
The presentation will be accessible via live webcast through the Events and Presentations section, with a replay available for viewing after the event.
Bicara Therapeutics (Nasdaq: BCAX) has initiated patient enrollment in FORTIFI-HN01, a pivotal Phase 2/3 trial evaluating ficerafusp alfa in combination with pembrolizumab for first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
The global, randomized, double-blinded trial aims to enroll approximately 650 patients with R/M HNSCC, excluding HPV-positive oropharyngeal cases. Patients must have a PD-L1 CPS ≥1 and no prior systemic therapy in the R/M setting. The study's primary endpoints include overall response rate and overall survival.
Ficerafusp alfa is a first-in-class bifunctional antibody targeting EGFR and TGF-β. The trial's design was supported by encouraging interim Phase 1/1b data showing durable and meaningful anti-tumor activity when combined with pembrolizumab.
Bicara Therapeutics (Nasdaq: BCAX) presented Phase 1/1b dose expansion results for ficerafusp alfa combined with pembrolizumab in treating advanced squamous cancer of the anal canal (SCAC). The study involved 28 patients who received 1-2 prior chemotherapy lines.
Key results include a 25.0% confirmed overall response rate (7/28 patients), with 6 partial responses and 1 complete response. The median progression-free survival was 2.9 months, with a 40.7% PFS rate at 12 months. Treatment-related adverse events included acneiform dermatitis (57.1%), epistaxis (50.0%), and pruritus (46.4%).
Ficerafusp alfa is a first-in-class bifunctional antibody targeting EGFR and TGF-β. The data suggests improved efficacy compared to historical pembrolizumab monotherapy in SCAC, with responses observed even in patients with liver metastases.
Bicara Therapeutics (Nasdaq: BCAX) reported Q3 2024 financial results and business updates. The company completed an upsized IPO raising $362 million in gross proceeds and maintains a strong financial position with $521 million in cash, expected to fund operations into H1 2029. The company is preparing to initiate FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa for head and neck cancer treatment. Current Phase 1/1b trial shows promising results with 64% overall response rate and 18% complete response rate. Q3 financial results show R&D expenses of $15.9 million and G&A expenses of $4.8 million, with a net loss of $17.5 million.
Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, has announced its participation in the Stifel 2024 Healthcare Conference. CEO Claire Mazumdar will deliver a presentation on November 19, 2024 at 9:10 a.m. ET in New York. The presentation will be accessible via live webcast on Bicara's website, with a replay available for approximately 90 days afterward.
Bicara Therapeutics (Nasdaq: BCAX) has successfully closed its initial public offering (IPO) of 20,125,000 shares of common stock at $18.00 per share, raising gross proceeds of approximately $362 million. The offering included the full exercise of the underwriters' option to purchase an additional 2,625,000 shares. Trading of Bicara's shares on the Nasdaq Global Market began on September 13, 2024, under the ticker symbol 'BCAX'.
The IPO was jointly managed by Morgan Stanley, TD Cowen, Cantor, and Stifel as bookrunners. Bicara Therapeutics, a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, will use the proceeds to advance its research and development efforts.
Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company, has announced the pricing of its upsized initial public offering. The company is offering 17,500,000 shares of common stock at $18.00 per share. Trading is expected to begin on the Nasdaq Global Market on September 13, 2024, under the ticker symbol 'BCAX'. The offering is set to close on September 16, 2024.
Bicara has granted underwriters a 30-day option to purchase up to an additional 2,625,000 shares. The gross proceeds are expected to be approximately $315.00 million, excluding any exercise of the underwriters' option. Morgan Stanley, TD Cowen, Cantor, and Stifel are acting as joint bookrunners for the offering.
